Search Results
Your search for The ASCO Post matches 17389 pages
Showing 11701 - 11750William Sellers, MD, Appointed to Faculty at Broad Institute, Dana-Farber Cancer Institute, and Harvard Medical School
William Sellers, MD, a widely respected cancer researcher with extensive experience in cancer genomics and therapeutic discovery, is returning to the Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard, Dana-Farber Cancer Institute, and Harvard Medical School (HMS) as a...
ASCO Releases Criteria for High-Quality Clinical Pathways in Oncology
ASCO recently released its Criteria for High-Quality Clinical Pathways in Oncology, a set of 15 interrelated criteria that provide an overarching framework for assessing pathway programs in the United States. ASCO developed the criteria to guide stakeholders in assessing the quality, utility, and...
UNC Lineberger’s Michael R. Kosorok, PhD, Elected AAAS Fellow
University of North Carolina (UNC) Lineberger Comprehensive Cancer Center member Michael R. Kosorok, PhD, has been named a fellow of the American Association for the Advancement of Science (AAAS), the world’s largest general scientific society and publisher of the journal Science. Dr. Kosorok, who ...
Diana M. Eccles, MD, on Young Breast Cancer Patients: Results From the POSH Study
Diana M. Eccles, MD, of the University of Southampton, discusses findings from a study of sporadic and hereditary breast cancer and whether BRCA status affects outcome in young breast cancer patients (Abstract S2-03).
Sonja Vliek, MD, and Sabine Linn, MD, PhD, on Early Breast Cancer: Results of the TEAM IIb Trial
Sabine Linn, MD, PhD, and Sonja Vliek, MD, both of the Netherlands Cancer Institute, discuss study findings on adjuvant ibandronate in postmenopausal women with early breast cancer (Abstract S6-02).
Christine Laronga, MD, FACS, Elected President of the Association of Women Surgeons
Christine Laronga, MD, FACS, a surgical oncologist specializing in breast cancer at Moffitt Cancer Center, has been named President of the Association of Women Surgeons. The international organization has more than 1,800 members and represents 21 countries. “I am thrilled to be in this new...
ASH Launches Digital, Open-Access Journal Blood Advances at 2016 Annual Meeting
Blood has covered experimental and clinical hematologic research as the flagship journal of the American Society of Hematology (ASH). Launched officially on November 29, 2016, the open-access online journal Blood Advances will fill a niche that complements and expands on topics covered in Blood...
University of Hawaii Cancer Center Receives $3 Million R01 NCI Grant for Bladder Cancer Research
Charles Rosser, MD, MBA, FACS, Professor and Director of the Clinical Trials Office and Director of the Clinical and Translational Research Program at the University of Hawaii Cancer Center, received a 5-year National Cancer Institute (NCI) R01 grant worth more than $3 million. The grant is for...
Make Funding for Cancer Research a Global Priority, Say European and American Organizations
The European Organisation for Research and Treatment of Cancer (EORTC) and the American Association for Cancer Research (AACR) are calling on policymakers and leaders throughout the world to provide robust and sustained funding for cancer research. The two organizations say there has been a...
ASH Honors Member of Congress and Former NCI Grants Chief With Service Awards
The American Society of Hematology (ASH) recognized Representative David McKinley (R-WV) and Roy Wu, PhD, former Chief of the Clinical Grants and Contracts Branch for the Cancer Therapy Evaluation Program at the National Cancer Institute (NCI), with awards for their outstanding advocacy for...
Treatment of Early HER2-Positive Breast Cancer: One Size Does Not Fit All
Despite the routine use of HER2 blockade in early HER2-positive breast cancer, clinicians can always benefit from a refresher on key treatment considerations. Clinical pearls and controversial issues were the topic of a presentation at the 14th Annual School of Breast Oncology at Emory University, ...
Reagan-Udall Foundation Announces Appointments of Ellen V. Sigal, PhD, and Richard L. Schilsky, MD
The Reagan-Udall Foundation for the U.S. Food and Drug Administration (FDA), an independent nonprofit organization that works to advance regulatory science to help support the scientific mission of the FDA, has elected Ellen V. Sigal, PhD, as its new Chairman, and Richard L. Schilsky, MD, as Vice ...
The FDA Ensures Quality and Safety of Generic Drugs in the United States
The U.S. Food and Drug Administration’s (FDA) generic drug program has substantially increased the availability of affordable, high-quality drugs in the United States. It is arguably the only really effective health-care cost–containment program. The more than 10,000 generic drugs currently...
David Tuveson, MD, PhD, Named Director of the Cold Spring Harbor Laboratory Cancer Center
David Tuveson, MD, PhD, will succeed Bruce Stillman, AO, FAA, FRS, as Director of the Cold Spring Harbor Laboratory Cancer Center. Dr. Tuveson is the Roy J. Zuckerberg Professor of Cancer Research at Cold Spring Harbor Laboratory, the Head of the Lustgarten Foundation Pancreatic Cancer Research...
NCCN Imaging Appropriate Use Criteria Published for 15 Additional Guidelines
The National Comprehensive Cancer Network® (NCCN®), a Centers for Medicare & Medicaid Services (CMS)-approved provider-led entity for imaging appropriate use criteria, continues to build its library of these standards and has published NCCN Imaging Appropriate Use Criteria™ for an additional 15 ...
Fergus J. Couch, PhD, and Max S. Wicha, MD, Recognized for Significant Contributions to Breast Cancer Research at 2016 SABCS
The American Association for Cancer Research (AACR) honored two renowned researchers for their work in breast cancer at the 2016 San Antonio Breast Cancer Symposium (SABCS), held December 6–10 in San Antonio, Texas. Fergus J. Couch, PhD, of the Mayo Clinic, will receive the 9th Annual AACR...
Reducing the Risk of Oral Complications During and After Cancer Therapy
According to the National Institutes of Health,1 nearly all patients with head and neck malignancies receiving high-dose radiation therapy; approximately 80% of patients undergoing stem cell transplantation; and about 40% of patients receiving chemotherapy will experience oral complications that...
SABCS 2016: Extended Letrozole Therapy Showed Limited Benefit in Postmenopausal Women With Early-Stage, Hormone Receptor–Positive Breast Cancer
Five additional years of hormone therapy with letrozole following an initial 5 years of aromatase inhibitor-based adjuvant hormone therapy did not demonstrate a statistical improvement in disease-free survival or overall survival in postmenopausal women with early-stage hormone...
SABCS 2016: Adding Everolimus to Fulvestrant Improved Outcomes for Postmenopausal Patients With Hormone Receptor–Positive Breast Cancer
Progression-free survival was more than doubled for patients with metastatic hormone receptor–positive, HER2-negative breast cancer resistant to aromatase inhibitor therapy by adding everolimus (Afinitor) to treatment with the endocrine therapeutic fulvestrant (Faslodex), according to data...
SABCS 2016: Genomic Sequencing of Treatment-Resistant Metastatic Breast Cancer Reveals Clinically Relevant Genetic Alterations
Genomic sequencing of estrogen receptor–positive metastatic breast cancer that had become resistant to therapies revealed multiple genomic and molecular alterations that were not present in the primary tumor samples, with implications for choice of next therapy, clinical trial eligibility,...
ASCO Praises Congress for Accelerating the Development and Delivery of Cancer Treatment With 21st Century Cures Act
In a statement released December 7, ASCO President Daniel F. Hayes, MD, FACP, FASCO, said, “ASCO applauds the U.S. Senate for their decisive vote today to pass the 21st Century Cures Act and authorize funding for the Beau Biden Cancer Moonshot and National Institutes of Health Innovation ...
City of Hope’s Ravi Salgia, MD, PhD, Receives 2016 Asclepius Award From the Bonnie J. Addario Lung Cancer Foundation
City of Hope’s Ravi Salgia, MD, PhD, Chair of the Department of Medical Oncology and Therapeutics Research, has received an accolade that recognizes his decades-long dedication to treating patients with lung cancer and researching new therapies. Dr. Salgia received the 2016 Asclepius Award from...
Cancer Metastasis International Symposium Abstract Award Winners Announced
The Organizing Committee for the 7th International Cancer Metastasis International Symposium has announced the abstract award winners for the meeting. The winners will be presented during the upcoming meeting, “Cancer Metastasis Through the Lymphovascular System: Biology and Treatment,” to be held...
Randi Kaplan, LMSW, Named Schwartz Center’s 2016 National Compassionate Caregiver of the Year
The Schwartz Center for Compassionate Healthcare, a national leader in providing compassionate care to patients and caregivers, has named Randi Kaplan, LMSW, Director of the Arthur D. Emil Caregiver Support Center at Montefiore, the National Compassionate Caregiver of the Year. The prestigious...
Center for Leukemia and Lymphoma Research at UNMC Renamed Dr. James O. Armitage Center for Leukemia and Lymphoma Research
The University of Nebraska Board of Regents voted to rename an area of the University of Nebraska Medical Center (UNMC) in honor of a longtime professor who has made extraordinary contributions to the institution. The Center for Leukemia and Lymphoma Research, established in 2003, was renamed by...
Johns Hopkins Kimmel Cancer Center Expands Cancer Care and Research Facility at Sibley Memorial Hospital in Washington, DC
Cancer experts from the Johns Hopkins Kimmel Cancer Center are now embedded in a newly expanded facility within Johns Hopkins Medicine–owned Sibley Memorial Hospital in northwest Washington, DC. Sibley recently opened the 30,000-square-foot medical oncology facility—part of its new...
NCI Study Affirms There Is No Safe Level of Smoking
People who consistently smoked an average of less than 1 cigarette per day over their lifetime had a 64% higher risk of earlier death than never-smokers, and those who smoked between 1 and 10 cigarettes a day had an 87% higher risk of earlier death than never-smokers, according to a new study from...
Expert Point of View: Steven Piantadosi, MD, PhD
In an interview with The ASCO Post, Steven Piantadosi, MD, PhD, Professor of Medicine and Director of the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai in Los Angeles, expressed enthusiasm for the Oncology Research Information Exchange Network (ORIEN) network of data-sharing. “With...
Liquid Biopsies Identify Molecular Alterations Driving Drug Resistance in Nearly 80% of Patients With Gastrointestinal Cancers
Liquid biopsy technologies are increasingly being used to detect genetic mutations in tumors, giving clinicians the opportunity to see in real time how a patient’s cancer may or may not be responding to treatment. In a study presented recently at the 28th EORTC-NCI-AACR Symposium on Molecular...
Noteworthy Antitumor Activity Seen in Phase I Studies of PDGFRα and KIT Mutation Inhibitors
Two studies presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Munich focused on the inhibition of mutations in the KIT and PDGFRα oncogenes. These genes encode receptor tyrosine kinases, and when they are mutated, cell signaling malfunctions, leading to...
City of Hope, Translational Genomics Research Institute Combine to Advance Precision Medicine and Speed Translational Research
City of Hope and Translational Genomics Research Institute (TGen) have announced an alliance to make precision medicine a reality for patients. This alliance enables both institutes to complement each other in their common areas of research and patient care, with City of Hope providing a...
FDA Approves Daratumumab in Combination Therapy for Patients With Multiple Myeloma Receiving at Least One Prior Treatment
On November 21, 2016, the U.S. Food and Drug Administration (FDA) approved daratumumab (Darzalex) in combination with lenalidomide (Revlimid) and dexamethasone or bortezomib (Velcade) and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior...
MD Anderson Cancer Center Marks 75 Years of Research to End Cancer
In November, The University of Texas MD Anderson Cancer Center celebrated its 75th anniversary with a week-long series of events that raised nearly $15 million to support its efforts in patient care and in the investigation and treatment of cancer. Housed on 16 million square feet in the city of...
Experts Consider the New Immunotherapy Paradigm in Advanced Lung Cancer
One immune checkpoint inhibitor has now moved to the front of the line for treating advanced non–small cell lung cancer (NSCLC). Based on pivotal studies presented at the 2016 European Society for Medical Oncology (ESMO) Congress, pembrolizumab (Keytruda) became a first-line option, and it is...
ASH 2016: Additions to Standard Multiple Myeloma Therapy Do Not Appear to Yield Additional Benefit
Trial results presented by Stadtmauer during the 58th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego (Abstract LBA-1) suggest two therapies that are often added to standard therapy in patients with multiple myeloma do not improve rates of progression-free survival ...
ASH 2016: Children With Down Syndrome and ALL Fare as Well as Other Children Treated on ALL Consortium Protocols
Despite an elevated risk of toxicity from chemotherapy, children with Down syndrome and acute lymphoblastic leukemia (ALL) did not experience higher rates of relapse or treatment-related mortality compared with other children treated on Dana-Farber Cancer Institute ALL Consortium Protocols,...
ASH 2016: Ibrutinib and TGR-1202 Combination Yields Encouraging Results in Patients With Relapsed Forms of Leukemia or Lymphoma
A combination of two targeted agents has demonstrated safety as well as encouraging signs of effectiveness in a phase I clinical trial in patients with relapsed or hard-to-treat chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL). Davids et al reported the findings at the 58th American ...
ASH 2016: New Data Shed Light on Potential Advantages of Pacritinib for Patients With Myelofibrosis
Compared with standard therapy, pacritinib significantly reduces spleen size among people with myelofibrosis who have very low levels of platelets, according to a late-breaking study presented by Mascarenhas et al during the 58th American Society of Hematology (ASH) Annual Meeting & Exposition...
ASH 2016: IKZF1 Gene Mutations Found to Increase Hereditary Risk for Acute Lymphocytic Leukemia in Children
A late-breaking abstract being presented by Churchman et al during the 58th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego (Abstract LBA-2) identifies inherited genetic mutations in the gene IKZF1 that confer a higher likelihood of developing pediatric...
ASH 2016: Ibrutinib Found Helpful in Treating Graft-vs-Host Disease After Stem Cell Transplant
A late-breaking abstract presented by Miklos et al during the 58th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego (Abstract LBA-3) showed patients who experience graft-vs-host disease (GVHD) after stem cell transplantation that is not resolved by corticosteroid...
Martin Schrappe, MD, on Childhood ALL: Study Results on Reducing Treatment Burden (German Language Version) 
Martin Schrappe, MD, of Christian-Albrechts University Kiel, discusses in German study findings on reduced intensity delayed intensification in standard-risk patients defined by minimal residual disease in childhood acute lymphoblastic leukemia (Abstract 4).
Robert E. Marcus, MD, on Follicular Lymphoma: Results From the GALLIUM Trial
Robert E. Marcus, MD, of Kings College Hospital, discusses study findings on obinutuzumab-based induction and maintenance in patients with previously untreated disease (Abstract 6).
Julie Vose, MD, MBA, and Anjali Advani, MD, on AML: Results of Two Trials on Vadastuximab Talirine
Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Anjali Advani, MD, of the Cleveland Clinic, discuss study findings on vadastuximab talirine as monotherapy and, in another trial, vadastuximab talirine plus hypomethylating agents in older patients with AML (Abstracts 590, 591).
Julie Vose, MD, MBA, and Mhairi Copland, MB, ChB, PhD, on CML: Data From the British DESTINY Study
Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Mhairi Copland, MB, ChB, PhD, of the Paul O’Gorman Leukaemia Research Centre at the University of Glasgow, discuss decreasing the dose of tyrosine kinase inhibitors in CML patients with stable molecular responses (Abstract 938).
Harry P. Erba, MD, PhD, on AML: Early Study Results on Vadastuximab Talirine
Harry P. Erba, MD, PhD, of the University of Alabama at Birmingham, discusses phase Ib findings on vadastuximab talirine in combination with 7+3 induction therapy for patients with newly diagnosed AML (Abstract 211).
Jeffrey E. Lancet, MD, on AML: Subgroup Analysis of a Phase III Trial
Jeffrey E. Lancet, MD, of the H. Lee Moffitt Cancer Center and Research Institute, discusses study findings on survival following allogeneic hematopoietic cell transplantation in older, high-risk acute myeloid leukemia patients initially treated with CPX-351 liposome injection vs standard...
Stephen M. Ansell, MD, PhD, on Hematologic Malignancies: Results of the CheckMate 039 Trial
Stephen M. Ansell, MD, PhD, of the Mayo Clinic, discusses phase I study findings on nivolumab in combination with ipilimumab for relapsed or refractory disease (Abstract 183).
Terry J. Fry, MD, on ALL: MRD and CAR Therapy
Terry J. Fry, MD, of the Pediatric Oncology Branch of the National Cancer Institute, discusses minimal residual disease–negative complete remissions following anti-CD22 chimeric antigen receptor in children and young adults with relapsed/refractory acute lymphoblastic leukemia (Abstract 650).
Martin Schrappe, MD, on Childhood ALL: Study Results on Reducing Treatment Burden
Martin Schrappe, MD, of Christian-Albrechts University Kiel, discusses study findings on reduced intensity delayed intensification in standard-risk patients defined by minimal residual disease in childhood acute lymphoblastic leukemia (Abstract 4).
Steven Le Gouill, MD, PhD, on Mantle Cell Lymphoma: Final Results From the LyMa Trial (French Language Version) 
Steven Le Gouill, MD, PhD, of Nantes University Hospital and INSERM, discusses in French study findings from the Lysa/Goelams Group on rituximab maintenance after autologous stem cell transplantation in younger patients with mantle cell lymphoma (Abstract 145).
